Mcc950

MCC950 (AbMole BioScience, USA) is a potent and selective small molecule inhibitor of NLRP3 that can block NLRP3 activation at nanomolar concentrations. MCC950 was dissolved in DMSO as a stocked solution and then diluted with PBS as a work solution. According to the previous research [19 (link)], MCC950 was administered intraperitoneally to rats (10 mg/kg) at day 3, 4, and 5 post-modeling and then once every 2 days. The rats in the control group were intraperitoneally injected with PBS (10 mg/kg) at the same time.

Thirty mice were assigned randomly into five groups (n = 6 each): (1) phosphate-buffered saline control (Con); (2) MCC950 control (MCC); (3) OVAlbumin- (OVA-) induced lung allergic inflammatory group (OVA); (4) OVA group treated with sevoflurane (OVA + SVF); and (5) OVA group treated with MCC950 (OVA + MCC).
OVA sensitization was performed by intraperitoneal (i.p.) injection of 10 μg of OVA (Sigma, St. Louis, MO, USA) adsorbed to 1 mg of alum (potassium aluminium sulphate, Sangon Biotech, Shanghai, China) on day 0. Fourteen days later, the animals were challenged by 1% OVA solution for 30 min for 7 consecutive days. The control mice were sensitized and challenged with saline alone. Immediately after OVA provocation, the mice received 3% sevoflurane (Maruishi Pharmaceutical, Osaka, Japan) for 1 h from day 14 to 20. MCC950 (10 mg/kg, i.p.) (Abmole Bioscience Inc., USA), a recently-described small molecule inhibitor of the NLRP3 inflammasome, was administered every two days postchallenge with OVA for comparison. At 24 h after the final challenge, the mice were sacrificed, and bronchoalveolar lavage fluid (BALF) was collected. Half of each lung was stored at −80°C for Western blotting, and the other half was fixed overnight in buffered 4% formaldehyde solution for histology analysis.